Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sigala, S.
Right arrow Articles by Spano, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sigala, S.
Right arrow Articles by Spano, P.
Clinical Cancer Research Vol. 5, 1211-1218, May 1999
© 1999 American Association for Cancer Research


Cancer Biology, Immunology, Cytokines

Suppression of Telomerase, Reexpression of KAI1, and Abrogation of Tumorigenicity by Nerve Growth Factor in Prostate Cancer Cell Lines1

Sandra Sigala2, Isabella Faraoni, Daniela Botticini, Marcelo Paez-Pereda, Cristina Missale, Enzo Bonmassar and PierFranco Spano

Division of Pharmacology, Department of Biomedical Sciences and Biotechnology, Brescia University Medical School, 25124 Brescia, Italy [S. S., D. B., C. M., P. F. S.]; Melanoma Center, Instituto Dermopatico dell’Immacolata, Via Monti di Creta 104, 00167 Rome, Italy [I. F., E. B.]; and Clinical Institut, Department of Endocrinology, Max Planck Institute of Psychiatry, D-80804 Munich, Germany [M. P-P.]

Nerve growth factor (NGF) is expressed in the prostate, where it appears to be involved in the control of epithelial cell growth and differentiation. NGF production is decreased in prostate tumors. However, the role of this neurotrophin in the control of proliferation and progression of prostate cancers is still a matter of investigation.

Prostate adenocarcinomas are telomerase-positive tumors. Chronic exposure of DU145 and PC3 prostate tumor cell lines to NGF resulted in a dramatic down-regulation of telomerase activity. This effect was correlated in terms of concentrations and time with a remarkable down-regulation of cell proliferation both in vitro and in vivo but was not secondary to NGF-induced quiescence. No down-regulation of telomerase activity was, in fact, detectable during serum starvation-induced quiescence. LNCaP cells, which do not express NGF receptors, appear to be insensitive to the actions of NGF.

DU145 and PC3 cells do not express the KAI1 metastasis suppressor gene, which is present in the prostate and is progressively lost during the progression of prostate cancers. Chronic NGF treatment strongly induced the reexpression of this gene in these cell lines, and this effect was correlated with the suppression of their invasive potential in vitro. The data presented here suggest that NGF reverts two metastatic prostate cancer cell lines to slowly proliferating, noninvasive phenotypes characterized by a very low telomerase activity and by the expression of the KAI1 metastasis suppressor gene.




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
E. J. Chapman, G. Kelly, and M. A. Knowles
Genes Involved in Differentiation, Stem Cell Renewal, and Tumorigenesis Are Modulated in Telomerase-Immortalized Human Urothelial Cells
Mol. Cancer Res., July 1, 2008; 6(7): 1154 - 1168.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
F.-S. Liu, J.-T. Chen, J.-T. Dong, Y.-T. Hsieh, A.-J. Lin, E. Shih-Chu Ho, M.-J. Hung, and C.-H. Lu
KAI1 Metastasis Suppressor Gene Is Frequently Down-Regulated in Cervical Carcinoma
Am. J. Pathol., November 1, 2001; 159(5): 1629 - 1634.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Kuniyasu, P. Troncoso, D. Johnston, C. D. Bucana, E. Tahara, I. J. Fidler, and C. A. Pettaway
Relative Expression of Type IV Collagenase, E-cadherin, and Vascular Endothelial Growth Factor/Vascular Permeability Factor in Prostatectomy Specimens Distinguishes Organ-confined from Pathologically Advanced Prostate Cancers
Clin. Cancer Res., June 1, 2000; 6(6): 2295 - 2308.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.